(NASDAQ: SNDX) Syndax Pharmaceuticals's forecast annual revenue growth rate of 58.55% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.8%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.37%.
Syndax Pharmaceuticals's revenue in 2026 is $172,352,000.On average, 16 Wall Street analysts forecast SNDX's revenue for 2026 to be $31,527,303,040, with the lowest SNDX revenue forecast at $20,053,287,507, and the highest SNDX revenue forecast at $40,013,964,387. On average, 15 Wall Street analysts forecast SNDX's revenue for 2027 to be $45,171,935,241, with the lowest SNDX revenue forecast at $25,844,538,640, and the highest SNDX revenue forecast at $62,205,234,341.
In 2028, SNDX is forecast to generate $60,968,661,985 in revenue, with the lowest revenue forecast at $31,722,226,357 and the highest revenue forecast at $84,544,681,296.